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Abstract
Among different subgroups of pulmonary arterial hypertension (PAH), those associated with connective tissue diseases (CTDs) have
distinct hemodynamic and prognostic features; a correct etiologic diagnosis is thus mandatory.
To estimate frequency and prognosis of previously undiagnosed CTDs in a suspect idiopathic (i) PAH cohort.
Consecutive patients with PAH conﬁrmed by right heart catheterization referred at the Cardiology Division of our Hospital without a
previous rheumatological assessment or the occurrence of other conditions explaining PAH were checked for CTD by a clinical,
laboratory, and instrumental evaluation. Survival in each group has also been analyzed.
In our study 17 of 49 patients were classiﬁed as CTD-PAH, corresponding to a prevalence (95% CI) of 34.7% (21.7–49.6%).
ANA positivity had 94% (71.3–99.9%) sensitivity and 78.1% (60–90.7%) speciﬁcity for a diagnosis of CTD-PAH; Raynaud
phenomenon (RP) showed 83.3% (51.6–97.9%) sensitivity and 100% (90.5–100%) speciﬁcity for the diagnosis of Systemic
Sclerosis (SSc)-PAH. At diagnosis, SSc patients were older and had a lower creatinine clearance compared with iPAH and
other CTD-PAH. After a median follow-up of 44 (2–132) months, 18 of 49 (36.7%) patients died: 31.2% in the iPAH group, 20%
in the CTD-, and 58.3% in the SSc-PAH group. Mortality was signiﬁcantly higher in SSc-PAH (HR 3.32, 1.11–9.95, P<0.05)
versus iPAH.
We show a high prevalence of undiagnosed CTDs in patients with iPAH without a previous rheumatological assessment. All
patients with RP were diagnosed with SSc. Our data stress the importance of a rheumatological assessment in PAH, especially
because of the unfavorable prognostic impact of an associated SSc.
Abbreviations: 95CI = 95% conﬁdence interval, ANA = antinuclear antibodies, BNP = brain natriuretic peptide, CI = cardiac
index, CTD = connective tissue disease, HR = hazard ratio, MCTD = mixed connective tissue disease, PAH = pulmonary arterial
hypertension, PAP = pulmonary arterial pressure, PVR = pulmonary vascular resistances, RP = Raynaud phenomenon, SLE =
systemic lupus erythematosus, SSc = systemic sclerosis, UCTD = undifferentiated connective tissue disease.
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11. Introduction
Pulmonary arterial hypertension (PAH) is a pathophysiologic
alteration associated with a wide range of conditions,[1] including
connective tissue diseases (CTDs). PAH prevalence in CTDs
varies greatly, with the highest rates reported in mixed connective
tissue disease (MCTD) (21–29%), systemic lupus erythematosus
(SLE) (up to 14%),[2] and systemic sclerosis (SSc) (nearly 10%).[3]
PAH is more rarely observed in inﬂammatory myopathies[4] and
Sjögren syndrome (SS).[2] CTD-associated PAH has a poorer
prognosis[5,6] and worse cardiac dysfunction compared with
idiopathic PAH (iPAH).[7] Immunosuppressant drugs may be
helpful in some CTDs,[8,9] thus enlarging the spectrum of
available therapies.
Challenges of PAH diagnosis include clinically undetected
CTDs that may not have overtly developed or have been left
unidentiﬁed until PAH clinical manifestations, analogously to
what we have shown in other conditions such as pregnancy.[10]
International guidelines for PH diagnosis and management[11]
recommend identifying associated CTD and recently several new
diagnostic/classiﬁcation criteria have been proposed for many
CTDs.[12–14]. Starting from these assumptions, we aimed to
evaluate the prevalence of undiagnosed CTDs among patients
referred to a tertiary cardiology center to perform right
heart catheterization (RHC), without a previous rheumatology
referral.
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This study was approved by the local Ethic Committee of the
IRCCS Policlinico SanMatteo Foundation. After ethical approval
and informed consent obtained, the ﬁrst 50 patients with RHC-
conﬁrmed precapillary PAH, consecutively assessed at the
Cardiology Division of the University Hospital of Pavia from
September 2008 to November 2011, and satisfying inclusion
criteria were included in the analysis. Inclusion criteria were: no
previous CTDs diagnosis, no previous rheumatology assessments,
no overt or suspect concomitant diseases or conditions explaining
PAH before the referral to the tertiary cardiology center. Patients
have been referred to the cardiologist in the suspicion of PAH by
their general practitioner or by a nonrheumatologist specialty
doctor who evaluated them in the Accidents and Emergencies
Department with symptoms of right heart failure.
Patientswere evaluated forCTDs symptoms/signsoccurrence by
two expert rheumatologists (LC, and SR) and underwent nailfold-
capillaroscopy, Schirmer test, and unstimulated whole saliva ﬂow.
Chest computed tomography for both interstitial lung disease
(ILD) evaluation (high-resolution) and thromboembolisms exclu-
sion (angiographic technique) was carried out. Laboratory tests
included plasma creatinine, brain natriuretic peptide (BNP), ANA
(indirect immunoﬂuorescence), anti-ENA (ELiA), anti-dsDNA
(indirect immunoﬂuorescence), anti-cardiolipin, anti-B2glicopro-
tein I (ELISA)antibodies, LupusAnticoagulant (LAC),C3,C4,and
direct Coombs test. Autoantibodies and LAC were conﬁrmed in 2
determinations 6weeks apart. Creatinine clearancewas calculated
using Mayo quadratic formula.[15] Well-established and recently
published classiﬁcation criteria were used for the identiﬁcation of
CTD patients.[12–14,16–20] NYHA class (due to the limited number
of patients, classes I and II were considered one group as were
classes III and IV) and RHC results were collected and compared.
Survival for both incident and prevalent patients was computed
from the time of the ﬁrst RHC.2.1. Statistics
Prevalence of undiagnosed CTDs in iPAH patients was calculated
and presented with a 95% exact conﬁdence interval (95% CI).
Sensitivity and speciﬁcity of ANA and Raynaud phenomenon for
the diagnosis of CTD were calculated. The groups’ categorical
variables (sex, NYHA-class) were compared using the Fisher
exact test. Continuous variables (age, BNP, creatinine clearance,
mean PAPs, cardiac index, pulmonary vascular resistance at ﬁrst
RHC) were compared using nonparametric tests. Overall
differences were tested using the Kruskal–Wallis equality-of-
populations rank test. Post hoc paired comparisons were made
with iPAH as the reference category using the Mann–Whitney
two-sample statistic. Linear correlations between continuous
variables were evaluated calculating the Spearman rank correla-
tion coefﬁcient. The log-rank test and Cox regression analyses
were used to analyze survival. A 2-sided P value <0.05 was
considered statistically signiﬁcant. All analyses were performed
using Stata 11.1 (Stata Corp, College Station, TX).
3. Results
Of the ﬁrst 50 patients referred to the rheumatological assessment
from the cardiologists, one denied consent to the study. Finally,
we analyzed 49 patients (36 females, 13 males). After the
rheumatological (re)-assessment, 32 patients (65%; 21 F, 11M)
were conﬁrmed suffering of an idiopathic form of PAH, whereas
17 (15 F, 2M) were classiﬁed as having a CTD-associated2condition, corresponding to an estimated prevalence (95%CI) of
34.7% (21.7–49.6%). In particular, 12 had SSc (25%, 6 limited
cutaneous, 4 limited, 2 patients satisﬁed only the 2013ACR/
EULAR Classiﬁcation criteria; 11 F, 1M), 2 SLE (4%, 2 F), 2
UCTD (4%, 1 F, 1M), and 1 SS (2%, 1 F). The two SSc patients
satisfying the 2013ACR/EULAR criteria were ﬁrst classiﬁed as
UCTD at the beginning of the study.
CTDs features observed in reclassiﬁed patients were mainly
represented by Raynaud phenomenon (10 SSc), dysphagia (7 SSc),
teleangectasias (6SSc), and sclerodactyly (6SSc).The2SScpatients
withoutRaynaud phenomenonwereANApositive (homogeneous
pattern) and had puffy ﬁngers, pitting scars, teleangectasias,
nailfold capillaroscopy alterations, thus satisfying the 2013ACR/
EULAR classiﬁcation criteria[14] independently of PAH inclusion.
One patient with UCTD presented arthritis, fever, mild ILD and
ANA positivity, the other one was characterized by photosensitiv-
ity, alopecia,ANAtest, dry eyewithpositivityof Schirmer test.One
SLE patient had arthritis, oral ulcers, leukopenia, thrombocytope-
nia, ANA test positive, and hypocomplementemia, the other one
photosensitivity, malar rash, oral ulcers, serositis, ANA, and
antiphosholipid antibodies. Sjogren syndrome was diagnosed
according to symptoms (dry eyes andmouth), positivity of anti-Ro
antibodies, Schirmer test, unstimulated whole saliva ﬂow, and
minor salivary gland biopsy. The main laboratory and instrumen-
tal tests observed in reclassiﬁedpatientswereANApositivity (titers
≥1:160) (11 SSc, 5 other CTDs), anticentromere antibody
positivity (9 SSc), and positive nailfold-capillaroscopy (11 SSc).
SeveralCTD featureswere also observed in iPAHpatients (ANA in
8 cases, antiphospholipid-antibodies/LAC and alopecia in 2, fever
and anti-Ro positivity in 1 respectively) but did not affect patients’
reclassiﬁcation. ANApositivitywas associatedwith a sensitivity of
94% (95% CI 71.3–99.9%) and a speciﬁcity of 78.1%
(60–90.7%) for a diagnosis of CTD-associated-PAH; while
Raynaud phenomenon was associated with a sensitivity of
83.3% (95% CI 51.6–97.9%) and a speciﬁcity of 100%
(90.5–100%) for a diagnosis of SSc-associated-PAH. Table 1
gives all CTD characteristics observed in our study sample
according to patients’ reclassiﬁcation.
At PAHdiagnosis, SSc patients were older than thosewith iPAH
(73 (64.5–76.5) vs 58 (46.5–73) years, P=0.01), while the age of
iPAHvs all-CTDspatientswas not statistically different (P=0.24).
There was no difference in sex prevalence between the various
groups. The delay between respiratory symptoms onset and the
ﬁrst RHC did not differ between CTDs and iPAH as well as the
distribution of baseline NYHA classes (see Table 2). BNP levels
were lower in other-CTDs (215 (73–471) pg/mL) and iPAH
(median 214 (104–432) pg/mL) than in SSc (267.5 (202.5–667))
but the difference did not reach statistical signiﬁcance. Creatinine
clearance was reduced in SSc (74.9 (59.6–86.1) mL/min/1.73 m2)
with respect to iPAH (93.6 (62.8–106.8) mL/min/1.73 m2, P=
0.03). For what concerns the hemodynamic features, mean basal
PAPs, cardiac index (CI), and pulmonary vascular resistances
(PVR) did not vary between groups. Table 2 provides the
demographic, clinical, laboratory, andRHC features in all groups.
Finally, we observed an inverse linear relationship between
mPAP and CI (rho 0.62, P=0.007) in all CTD patients while
this association was not signiﬁcant in patients with iPAH (rho
0.11; P=0.54).
After a median follow-up of 44 (2–132) months, 18 of 49
(36.7%) patients were deceased: 10 of 32 (31.2%) in the iPAH
group, 1 of 5 (20%) in the CTD, and 7 of 12 (58.3%) in the SSc-
PAH group. Survival was signiﬁcantly lower in SSc-PAH (HR
3.32, 95% CI 1.11–9.95, P<0.05) versus iPAH while there was
Table 1
Connective tissue disease (CTD) signs and symptoms observed in our study population of PAH patients, according to their ﬁnal diagnosis.
All CTD
(17 patients) (n)
SSc associated PAH
(12 patients)
Other-CTDs
associated PAH (5 patients)
Idiopathic PAH
(32 patients)
Raynaud phenomenon 10 10 0 0
Scleroderma pattern (nailfold capillaroscopy) 11 10∗ 1 0
ANA + (≥1/160 IFI) 16 11 5 8
Anticentromere antibodies 9 9 0 0
Anti-Ro antibodies 4 2 2 1
Antiphospholipid antibodies or LAC 3 1 2 2
Teleangectasias 6 6 0 0
Sclerodactyly 6 6 0 0
Dysphagia 7 7 0 0
Pitting scars 1 1 0 0
Arthritis-arthralgias 3 1 2 0
Low degree ILD (Kazerooni score < 3) 3 2 1 0
Oral ulcers 2 0 2 0
Photosensitivity 3 1 2 0
Dry eye or mouth/Schirmer test and scialometry + 3/2 1/0 2/2 0
Serositis 2 1 1 0
Fever 1 0 1 0
Alopecia 11 0 1 2
Low platelet and WBC 1 0 1 1
ILD= interstitial lung disease, WBC=white blood cells.
∗
Scleroderma pattern active: 5 patients, Scleroderma pattern late: 5 patients.
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iPAH (Fig. 1). SSc patients were older than iPAH and correcting
the effect of an SSc diagnosis with age with respect to mortality in
an adjusted analysis resulted in a yet positive but no longer
signiﬁcant association compared with crude analysis (HR 1.61,
0.54–4.83).
4. Discussion
In our study, more than 30% of patients suspected or diagnosed
with iPAHhad an undiagnosed CTDs. Even if all CTDs should be
potentially considered, SSc is the most frequent one (24.4%). All
patients with this disease are now routinely screened for PAH
occurrence.[21,22] The features of PAH in established SSc have
been described in terms of epidemiology[3,23] and unique features
with respect to iPAH.[5–7,24] Tools such as the Cochin risk
prediction score[25] or the DETECT score[26] could help cliniciansTable 2
Main demographic, clinical, laboratory, and RHC differences betwee
SSc associate
PAH (12 patie
Female, n (%) 11 (91.7)
Age (years), median (IQR) 73 (64.5–76.
Delay between dyspnea onset and ﬁrst RHC (months), median (IQR) 8.5 (6–14.5)
NYHA class at ﬁrst RHC, n (%)
I/II 6 (50)
III/IV 6 (50)
BNP levels (pg/mL) at ﬁrst RHC, median (IQR) 267.5 (202.5–66
Creatinine clearance (mL/min/1.73 m2) at ﬁrst RHC, median (IQR) 74.9 (59.6–86.
Mean PAPs (mm Hg) at ﬁrst RHC, median (IQR) 47 (29–54)
Cardiac index (L/min/m2) at ﬁrst RHC, median (IQR) 2.25 (1.79–2.8
Pulmonary vascular resistances (dyne × sec × cm−5) at ﬁrst RHC 878 (705–112
BNP=brain natriuretic peptide, iPAH= idiopathic pulmonary arterial hypertension, IQR= interquartile ran
catheterization, SSc= systemic sclerosis, TD= connective tissue disease.
∗
With respect to conﬁrmed iPAH.
3to select SSc patients at higher risk for PAH development.
International guidelines (Authors/Task Force, Galie et al
2015[11]) suggested that occasional patients diagnosed with
iPAH could have an associated CTD, thus justifying the screening
for CTDs in iPAH patients;[11] however, to date, no studies
evaluating this aspect are available.
Classiﬁcation criteria for CTDs are continuously being
updated by international study groups to improve their sensitivity
and speciﬁcity, especially in the early phases of diseases.[12–14] In
the case of SSc, new criteria have been released in 2013 and PAH
is one of the new items included, acknowledging the fact that this
manifestation could represent the onset of the disease as the
ﬁrst non-Raynaud symptom.[14] In SSc duration of Raynaud
phenomenon can span many years before the disease manifests
itself.[27] The most important result of our study is not only that
undiagnosed CTD may be frequently identiﬁed in PAH patients,
but also that Raynaud phenomenon is strictly associated with an groups.
d
nts) P value
∗
Conﬁrmed iPAH
(32 patients) P value
∗
All CTD
associated PAH
(17 patients)
0.13 21 (65.6) 0.10 15 (88.2)
5) 0.01 58 (46.5–73) 0.24 67 (55–76)
0.14 6 (3.5–9) 0.21 8 (6–12)
0.50 20 (62.5) 1.00 10 (58.8)
12 (37.5) 7 (41.2)
7) 0.19 214 (104–432) 0.81 215 (73–471)
1) 0.03 93.6 (62.8–106.8) 0.11 82.7 (63.7–94.6)
0.23 47.5 (34–57) 0.12 44 (30–53)
5) 0.90 2.28 (1.84, 2.56) 0.77 2.27 (1.84, 2.7)
5) 0.47 791 (512.7–987) 0.88 748 (516–1028)
ge, NYHA=New York Heart Association, PAH=pulmonary arterial hypertension, RHC= right heart
Figure 1. Kaplan–Meier survival curves of the different PAH diagnostic groups.
∗
P<0.05.
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iPAH in the literature ranges from 5% to 30%,[28–31] and this
might be accounted by the high prevalence of an undiagnosed
rheumatic disease in these cohorts. Our results clearly indicate
that a careful rheumatological evaluation (including nailfold
capillaroscopy) should be considered to increase diagnosis
speciﬁcity in these patients and to reduce the risk of a hidden
SSc spectrum disorder. Beside capillaroscopy, autoantibody
proﬁling is also mandatory for the screening of SSc and other
CTDs in general.
We have previously demonstrated that a simple questionnaire
could identify a population with a 30% frequency of undiag-
nosed CTD in otherwise healthy pregnant women.[10] Results
from the present study suggest the potential utility of a similar
approach in PAH patients. Analogously to the effort made in the
ﬁeld of interstitial lung disease with the recent introduction of the
concept of interstitial pneumonia with autoimmune features[32]
we propose that a population of PAH patients show autoimmune
features which may rely undetected at a ﬁrst examination and
which require a multidisciplinary expertise and the mandatory
performance of ANA testing and capillaroscopy. Furthermore,
this approach is essential considering the continuous progresses
in the classiﬁcation and diagnosis of rheumatic conditions.
Moreover, the identiﬁcation of an underlying CTD is crucial as
the disease course is frequently complicated by disease-related
manifestations other than PAHwhich may affect the prognosis of
these patients. In SSc, for example, ILD may develop at any time
during the course of the disease and this may complicate PH
classiﬁcation (group 1 PAH vs group 3 PH associated with
chronic lung diseases) and subsequent treatment.[33] CTD-
associated PAH may beneﬁt from immunosuppressant therapies
beside classical therapies: SLE orMCTD patients may respond to
treatments combining cyclophosphamide and glucocorticoids,[8]
particularly in the early phases of the disease. To date, no cases of
UCTD-associated PAH have been reported in the literature and
the present study is the ﬁrst to link such condition to PAH.
Although age may discriminate patients with SSc from those with
iPAH,[7] our results showed that this difference is not helpful in
case of other CTDs occurrence. As previously described,[34] renal
function was lower in SSc patients and this is not unexpected
given the frequent subclinical kidney involvement in the
disease.[35] Given the impact of renal dysfunction on PAH
prognosis,[36] this may partially explain the worse survival of SSc-
associated PAH than iPAH.[7] Demographics, clinical, laboratory
and RHC results between groups were compared, in order to
identify factors that may help clinicians in CTD identiﬁcation and
to assess hemodynamic differences between these patients. RHC
parameters were substantially similar in the head-to-head4analysis. In CTDs we observed an inverse linear relationship
between mPAP and CI that was lacking in iPAH, thus suggesting
that cardiac function is more compromised in CTD patients.
Survival in our cohort is inﬂuenced by the diagnosis of SSc in the
univariate analysis, but this effect is dependent on the age
difference of SSc versus iPAH patients. Anyway, our results are in
line with the literature suggesting SSc-PAH as a deﬁnite and
worse—in prognosis—subset of patients. Despite the availability
of new promising therapies the survival of patients with SSc,
especially when it is complicated with pulmonary hypertension, is
still signiﬁcantly reduced when compared with the general
population.[37] Therefore, early diagnosis of patients with this
condition is of major importance. Assessment of patients with
Raynaud phenomenon to disclose patients with connective tissue
diseases may be a key symptom to disclose CTDs and SSc in
particular.
The small cohort that we analyzed is responsible for the lack of
signiﬁcance in the multivariate analysis of survival because of the
paucity of events in our follow-up. Beyond this latter limit, we
also acknowledge that we performed a single-center study that is
therefore open to the risk of selection bias and also to criticisms
on the feasibility of the application of such a quick referral where
the cardiologist and the rheumatologist are not in close
cooperation or even not in the same hospital. In this view, we
must consider that one recommendation of the management of
PH is to refer patients to a tertiary center, which in our view has to
encompass a rheumatology clinic.5. Conclusions
Our results show a high prevalence of undiagnosed CTDs in
patients classiﬁed or suspected with iPAH and without previous
rheumatology referrals. SSc is the preeminent CTD diagnosed in
the setting andRaynaudphenomenon is themain suspectﬁndingof
SSc that all clinicians should assess.Wehighlight the importance of
a multidisciplinary approach, which may result helpful with
regards to classiﬁcation and follow-up/therapeutic implications.References
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